VICTORIA

Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction

Patient / Population Intervention / Exposure Comparison Outcome

In 5,050 patients with worsening HFrEF (EF < 45%), vericiguat reduced cardiovascular death or first heart-failure hospitalisation compared with placebo.

5,050

Design

Double-blind placebo-controlled RCT, phase 3

Endpoint

Composite of death from cardiovascular causes or first hospitalisation for heart failure

Relevance

Result35.5% with vericiguat vs 38.5% with placebo (HR 0.90, 95% CI 0.82-0.98; P=0.02) over median 10.8 months.

Armstrong PW, et al. N Engl J Med. 2020;382(20):1883-1893. 10.1056/NEJMoa1915928

Discussion & critique

Modest relative benefit in a very high-risk, recently decompensated cohort, with no reduction in CV death alone. Added an oral soluble guanylate cyclase stimulator as an option for worsening HFrEF.